Vitamin D DeficiencyVitDTrackingNCT06292195
Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome
An observational study of Vitamin D Deficiency and Pregnancy, run by University of Évora at 3 sites in Portugal.
Trial summary
The VitDTracking study focuses on the relevance of maternal vitamin D levels and their association with prematurity, aiming to improve maternal and child health outcomes, particularly by reducing avoidable preterm births. In Portugal, vitamin D levels during pregnancy have never been studied. Read more about this study
- Who is it for?
- Ages 16 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Vitamin D Deficiency, Pregnancy
- What is being tested?
- Exposure
- How many people
- 2,000 participants
- Where
- 3 sitesPortugal
- Study dates
- 3 Nov 2023to 30 Jun 2027
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Pregnant women's in the Alentejo region
Who may be able to join
- Pregnant women's living in the Alentejo region aged 16 years or older, who after disclosure and clarification of doubts, agree to participate in the study with signed informed consent.
Who cannot join
- Language barrier (lack of basic understanding of Portuguese).
Trial locations and contacts
3 sites in 1 country.
Portugal3 sites
Unidade Local de Saúde do Baixo Alentejo
Beja, Beja District, 7801-849
Unidade Local de Saúde do Alentejo Central - Hospital Espirito Santo de Évora
Evora, Évora District, 7000-811
Unidade Local de Saúde do Norte Alentejano
Portalegre, Portalegre District, 7301-853
About this study
Official title: Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome Indicators in the Alentejo Region
The VitDTracking study focuses on the relevance of maternal vitamin D levels and their association with prematurity, aiming to improve maternal and child health outcomes, particularly by reducing avoidable preterm births. In Portugal, vitamin D levels during pregnancy have never been studied. Epidemiological data from other countries reveal a high prevalence of vitamin D deficiency/insufficiency, especially in pregnant women.
The hypovitaminoses prevalence remains high even with a supplementation dosage of 400 to 600 IU/day during pregnancy (dosage used in Portugal), which is considered as a suboptimal dose. This phenomenon is associated with adverse maternal and child outcomes, such as intrauterine growth restriction, preeclampsia, cholestasis, hypertension, and gestational diabetes as major causes of prematurity.
Additionally, the Portuguese population has a higher prevalence of genome alterations that confer a lower capacity to produce vitamin D from sunlight exposure. These genetic characteristics are present in about 19% of the population, representing a prevalence four times higher than the European average (19% versus 4.75%), leading to a higher predisposition to vitamin D deficiency.
Read the detailed description
This observational study involves the implementation of multicenter recruitment centers. Data collection will take place in healthcare organizations in the Alentejo region (Évora, Beja, Portalegre, and Elvas) with a minimum total sample of 1000 pregnant women, integrating both primary and specialized healthcare, with local healthcare professionals, doctors, and nurses as collaborators.
The study will measure vitamin D levels during pregnancy and their impact on outcome indicators related to prematurity. The aim is to assess the impact of the prevalence of vitamin D deficiency on prematurity outcomes. This involves monitoring vitamin D levels in prenatal and postnatal surveillance, adding this biomarker to routine blood collections. Biometric and biochemical data collection will occur at two distinct time points. The first collection will take place during the first prenatal surveillance appointment, preferably in the first trimester. The second collection will occur postpartum, during the hospitalization period.
The study will also assess maternal vitamin D deficiency and associated factors in the Alentejo region. It aims to identify the existence of genetic polymorphisms related to vitamin D and assess associations with adverse clinical outcomes related to prematurity. This involves requesting genetic analysis by the local medical collaborator and collecting saliva from the pregnant woman (non-invasive method) for the study of polymorphisms in seven genes, integrating the analysis of 18 genetic variants that play a role in the metabolism, transport, degradation and downstream pathways of vitamin D. Saliva samples from pregnant women will be collected during hospitalization before or after birth.
- Conditions
- Vitamin D Deficiency, Pregnancy
- Being tested
- Exposure
- Keywords
- Vitamin D, Pregnancy, Prematurity, Genetic polymorphisms
- Medical subject headings
- Vitamin D Deficiency, Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExposureOther
Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
| Study group | Role | What they receive |
|---|---|---|
| Cohort VitDTracking: Group 1- Pregnant women with vitamin D Sufficiency (≥30 ng/mL) | Not described Receives: Other: Exposure | |
| Cohort VitDTracking: Group 2 - Pregnant women with vitamin D Insufficiency (20-29 ng/mL) | Not described Receives: Other: Exposure | |
| Cohort VitDTracking: Group 3 - Pregnant women with vitamin D Deficiency (<20 ng/mL) | Not described Receives: Other: Exposure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in the rate of Prematurity with different maternal Vitamin D levels
Prematurity Rate in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in Birth Weight with different maternal Vitamin D levels
Birth Weight in grams
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in Apgar Scores with different maternal Vitamin D levels
Apgar Scores in Scale (<7 or ≥7)
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the number of admissions to the Neonatal Intensive Care Unit with different maternal Vitamin D levels
Number of admissions to the Neonatal Intensive Care Unit in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the Neonatal Morbidity rate with different maternal Vitamin D levels
Neonatal Morbidity rate in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the Neonatal Mortality rate with different maternal Vitamin D levels
Neonatal Mortality rate in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the number of Neonatal Infections with different maternal Vitamin D levels
Number of Neonatal Infections in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the Number of Congenital Malformation diagnoses with different maternal vitamin D levels
Number of Congenital Malformation diagnoses in percentage
Measured: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Differences in the presence of vitamin D-related polymorphisms with different maternal levels of vitamin D
Differences will be assessed following the defined outcome indicators related to prematurity
Measured: Saliva samples from pregnant women will be collected during admission to the hospital or up to 48 hours after delivery (after participant enrollment; single collection point)
Secondary outcomes (16)
Differences in maternal vitamin D levels between the three groups/cohorts related to prematurity
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to birth weight
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to Apgar scores
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to admission to the Neonatal Intensive Care Unit
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal morbidity
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal mortality
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal infections.
Measured: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to the diagnosis of congenital malformations
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with prematurity
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with birth weight
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with Apgar scores
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with admission to the Neonatal Intensive Care Unit.
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal morbidity
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal mortality
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal infections
Measured: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with the diagnosis of congenital malformations
Measured: Through study completion, an average of 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2024
- Study start3 Nov 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Vitamin D DeficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- University of Évora
- Sponsor type
- University, hospital or other
- Collaborators
- Comprehensive Health Research Center, Unidade Local De Saúde Do Norte Alentejano, Unidade local de Saúde do Baixo Alentejano, Unidade Local de Saúde do Alentejo Central, Universidade Nova de Lisboa, Instituto de Engenharia de Sistemas e Computadores - Inovação e Desenvolvimento de Lisboa (INESC-ID)
- Responsible party
- Principal investigator, Maria Olívia Pereira Barbosa, University of Évora
- Investigators
- Maria OP Barbosa, MSc; PhD student, Principal investigator, University of ÉvoraDulce Cruz, PhD, Principal investigator, University of ÉvoraAndré Rosário, PhD, Principal investigator, Universidade Nova de LisboaMarta Silvestre, PhD, Principal investigator, Universidade Nova de LisboaAna T Freitas, PhD, Principal investigator, Instituto de Engenharia de Sistemas e Computadores - Inovação e Desenvolvimento de Lisboa (INESC-ID)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06292195
- Sponsor's protocol ID
- VitDTracking
- Acronym
- VitDTracking
- Status last verified
- Mar 2026
- First submitted
- 19 Feb 2024
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Barbosa O, Freitas AT, Silvestre MP, Moreira-Rosario A, Aguiar P, Regua AI, Madaleno T, Almeida M, Cruz D. Effects of Maternal Vitamin D Levels on Prematurity: Feasibility Study in a Multicenter Observational Pilot. Nutrients. 2025 Mar 27;17(7):1160. doi: 10.3390/nu17071160.
PubMed 40218918
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome Indicators in the Alentejo Region
- ClinicalTrials.gov ID
- NCT06292195
- Acronym / sponsor ID
- VitDTracking / VitDTracking
- Conditions
- Vitamin D Deficiency, Pregnancy
- Keywords
- Vitamin D, Pregnancy, Prematurity, Genetic polymorphisms
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,000 participants (actual)
- Lead sponsor
- University of ÉvoraUniversity, hospital or other
- Collaborators
- Comprehensive Health Research Center, Unidade Local De Saúde Do Norte Alentejano, Unidade local de Saúde do Baixo Alentejano, Unidade Local de Saúde do Alentejo Central, Universidade Nova de Lisboa, Instituto de Engenharia de Sistemas e Computadores - Inovação e Desenvolvimento de Lisboa (INESC-ID)
- Study start
- 3 Nov 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 5 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The VitDTracking study focuses on the relevance of maternal vitamin D levels and their association with prematurity, aiming to improve maternal and child health outcomes, particularly by reducing avoidable preterm births. In Portugal, vitamin D levels during pregnancy have never been studied. Epidemiological data from other countries reveal a high prevalence of vitamin D deficiency/insufficiency, especially in pregnant women.
The hypovitaminoses prevalence remains high even with a supplementation dosage of 400 to 600 IU/day during pregnancy (dosage used in Portugal), which is considered as a suboptimal dose. This phenomenon is associated with adverse maternal and child outcomes, such as intrauterine growth restriction, preeclampsia, cholestasis, hypertension, and gestational diabetes as major causes of prematurity.
Additionally, the Portuguese population has a higher prevalence of genome alterations that confer a lower capacity to produce vitamin D from sunlight exposure. These genetic characteristics are present in about 19% of the population, representing a prevalence four times higher than the European average (19% versus 4.75%), leading to a higher predisposition to vitamin D deficiency.
Detailed description
This observational study involves the implementation of multicenter recruitment centers. Data collection will take place in healthcare organizations in the Alentejo region (Évora, Beja, Portalegre, and Elvas) with a minimum total sample of 1000 pregnant women, integrating both primary and specialized healthcare, with local healthcare professionals, doctors, and nurses as collaborators.
The study will measure vitamin D levels during pregnancy and their impact on outcome indicators related to prematurity. The aim is to assess the impact of the prevalence of vitamin D deficiency on prematurity outcomes. This involves monitoring vitamin D levels in prenatal and postnatal surveillance, adding this biomarker to routine blood collections. Biometric and biochemical data collection will occur at two distinct time points. The first collection will take place during the first prenatal surveillance appointment, preferably in the first trimester. The second collection will occur postpartum, during the hospitalization period.
The study will also assess maternal vitamin D deficiency and associated factors in the Alentejo region. It aims to identify the existence of genetic polymorphisms related to vitamin D and assess associations with adverse clinical outcomes related to prematurity. This involves requesting genetic analysis by the local medical collaborator and collecting saliva from the pregnant woman (non-invasive method) for the study of polymorphisms in seven genes, integrating the analysis of 18 genetic variants that play a role in the metabolism, transport, degradation and downstream pathways of vitamin D. Saliva samples from pregnant women will be collected during hospitalization before or after birth.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort VitDTracking: Group 1- Pregnant women with vitamin D Sufficiency (≥30 ng/mL) | – | Other: Exposure |
| Cohort VitDTracking: Group 2 - Pregnant women with vitamin D Insufficiency (20-29 ng/mL) | – | Other: Exposure |
| Cohort VitDTracking: Group 3 - Pregnant women with vitamin D Deficiency (<20 ng/mL) | – | Other: Exposure |
Who may qualify
- Ages
- 16 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Pregnant women's in the Alentejo region
Key inclusion criteria (1 listed)
- Pregnant women's living in the Alentejo region aged 16 years or older, who after disclosure and clarification of doubts, agree to participate in the study with signed informed consent.
Key exclusion criteria (1 listed)
- Language barrier (lack of basic understanding of Portuguese).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExposureMaternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels) | Other | Cohort VitDTracking: Group 1- Pregnant women with vitamin D Sufficiency (≥30 ng/mL), Cohort VitDTracking: Group 2 - Pregnant women with vitamin D Insufficiency (20-29 ng/mL), Cohort VitDTracking: Group 3 - Pregnant women with vitamin D Deficiency (<20 ng/mL) |
Primary outcome
Differences in the rate of Prematurity with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Prematurity Rate in percentage
Differences in Birth Weight with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Birth Weight in grams
Differences in Apgar Scores with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Apgar Scores in Scale (<7 or ≥7)
Differences in the number of admissions to the Neonatal Intensive Care Unit with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Number of admissions to the Neonatal Intensive Care Unit in percentage
Differences in the Neonatal Morbidity rate with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Neonatal Morbidity rate in percentage
Differences in the Neonatal Mortality rate with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Neonatal Mortality rate in percentage
Differences in the number of Neonatal Infections with different maternal Vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Number of Neonatal Infections in percentage
Differences in the Number of Congenital Malformation diagnoses with different maternal vitamin D levels
Time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)
Number of Congenital Malformation diagnoses in percentage
Differences in the presence of vitamin D-related polymorphisms with different maternal levels of vitamin D
Time frame: Saliva samples from pregnant women will be collected during admission to the hospital or up to 48 hours after delivery (after participant enrollment; single collection point)
Differences will be assessed following the defined outcome indicators related to prematurity
16 secondary outcomes
Differences in maternal vitamin D levels between the three groups/cohorts related to prematurity
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to birth weight
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to Apgar scores
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to admission to the Neonatal Intensive Care Unit
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal morbidity
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal mortality
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal infections.
Time frame: Through study completion, an average of 3 months
Differences in maternal vitamin D levels between the three groups/cohorts related to the diagnosis of congenital malformations
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with prematurity
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with birth weight
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with Apgar scores
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with admission to the Neonatal Intensive Care Unit.
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal morbidity
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal mortality
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal infections
Time frame: Through study completion, an average of 3 months
Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with the diagnosis of congenital malformations
Time frame: Through study completion, an average of 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Derived from this study: PubMed 40218918Barbosa O, Freitas AT, Silvestre MP, Moreira-Rosario A, Aguiar P, Regua AI, Madaleno T, Almeida M, Cruz D. Effects of Maternal Vitamin D Levels on Prematurity: Feasibility Study in a Multicenter Observational Pilot. Nutrients. 2025 Mar 27;17(7):1160. doi: 10.3390/nu17071160.
- Individual participant dataSharing planned: No
Related trials for Vitamin D Deficiency
RecruitingPhase 1/2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
X-linked Hypophosphatemia
Not yet recruitingPhase 2
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial
Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function
Recruiting
Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS), Vitamin D Deficiency
RecruitingObservational study
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
FGF23-related Hypophosphataemic Rickets and Osteomalacia
Not yet recruiting
Effect of Vitamin D Supplementation Added to Iron Therapy in Children With Iron Deficiency Anemia
Iron Deficiency Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria OP Barbosa, MSc; PhD student principal investigator
University of Évora
Dulce Cruz, PhD principal investigator
University of Évora
André Rosário, PhD principal investigator
Universidade Nova de Lisboa
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vitamin D Deficiency and Pregnancy, run by University of Évora at 3 sites in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in the rate of Prematurity with different maternal Vitamin D levels (time frame: Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06292195, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.